Tools
Upgrade to Pro 🌟

Upgrade for Pro stock ideas, Al signals, and more search.

Learn More

ENSC

Ensysce Biosciences, Inc. · NASDAQ

Performance

-2.8%

1W

+268.79%

1M

+63.93%

3M

+5.08%

6M

-38.14%

YTD

-27.14%

1Y

Profile

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative which releases clinically effective oxycodone; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse. The company is based in La Jolla, California.

Technical Analysis of ENSC 2024-11-20

The stock exhibits a strong bullish sentiment with a Moving Average Score of 83, indicating robust upward momentum, while the Oscillators Score of 40 suggests a neutral stance, and the overall Technical Score of 61 reinforces a positive outlook. This combination implies that despite some neutral signals, the prevailing trend remains favorable fo...
Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

See more ...

Stock Analysis of ENSC

Stock Rank

See more ...

Recent News & Updates

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.